Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and Combination Therapy in Alzheimer's Disease
NCT07135245Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Sep 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of semaglutide in Alzheimer's disease (AD). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07135245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135245.